Literature DB >> 12645035

Progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease using [18F]CFT PET.

Elina Nurmi1, Jörgen Bergman, Olli Eskola, Olof Solin, Tero Vahlberg, Pirkko Sonninen, Juha O Rinne.   

Abstract

The aim of this study was to investigate the progression of dopaminergic hypofunction in striatal subregions in Parkinson's disease (PD). We studied 12 patients with early PD and 11 healthy controls with a dopamine transporter ligand 2beta-carbomethoxy-3beta-(4-[(18)F]-fluorophenyl)tropane ([(18)F]CFT) positron emission tomography (PET). The PET scan was carried out twice with an average interval of 2.2 years. The regions of interest (anterior and posterior putamen, caudate nucleus, and cerebellum) were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images, and copied onto the PET images. At the first PET scan in PD patients, the [(18)F]CFT uptake in the anterior putamen was 1.92 +/- 0.67, which was 45% of the control mean, and in the posterior putamen 1.02 +/- 0.55, being only 27% of the control mean. For the caudate nucleus the corresponding figure was 2.55 +/- 0.58 (71% of the control mean). The uptake ratios had declined significantly by the time of the second PET scan and the absolute annual rate of decline of the tracer uptake was 0.23 +/- 0.14 (P < 0.001) in the anterior putamen, 0.13 +/- 0.13 (P = 0.005) in the posterior putamen, and 0.20 +/- 0.15 (P < 0.001) in the caudate nucleus. There was a statistically significant difference of the decline in the tracer uptake between the anterior and posterior putamen (P = 0.033). When the rate of progression was calculated compared to the normal control mean, the rate of annual decline was 5.3% in the anterior putamen, 3.3% in the posterior putamen, and 5.6% in the caudate nucleus, without significant changes among striatal subregions (P = 0.10). When ipsi- and contralateral sides were analyzed separately, the absolute decline of [(18)F]CFT uptake in the putamen was higher in the side ipsilateral to the predominant symptoms than in the contralateral side (P = 0.035 for anterior putamen and P = 0.026 for posterior putamen). In the caudate nucleus the absolute decline was not different between ipsi- and contralateral sides (P = 0.76). In healthy controls, no significant decline of [(18)F]CFT uptake was detected. The results are suggestive of slower progression in the posterior putamen, where the disease is more advanced, but studies to follow up the same patient at several time points are needed to resolve this question. Synapse 48:109-115, 2003. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12645035     DOI: 10.1002/syn.10192

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  16 in total

1.  Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia.

Authors:  Blanca Ramírez-Ruiz; María José Martí; Eduardo Tolosa; David Bartrés-Faz; Chistopher Summerfield; Pilar Salgado-Pineda; Beatriz Gómez-Ansón; Carme Junqué
Journal:  J Neurol       Date:  2005-07-05       Impact factor: 4.849

2.  Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT.

Authors:  Sean J Colloby; E David Williams; David J Burn; Jim J Lloyd; Ian G McKeith; John T O'Brien
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06-02       Impact factor: 9.236

Review 3.  PET/CT in diagnosis of movement disorders.

Authors:  Valentina Berti; Alberto Pupi; Lisa Mosconi
Journal:  Ann N Y Acad Sci       Date:  2011-06       Impact factor: 5.691

4.  Rate of 6-[18F]fluorodopa uptake decline in striatal subregions in Parkinson's disease.

Authors:  Catherine L Gallagher; Terrence R Oakes; Sterling C Johnson; Moo K Chung; James E Holden; Barbara B Bendlin; Donald G McLaren; Guofan Xu; Robert J Nickles; Robert Pyzalski; Onofre DeJesus; W Douglas Brown
Journal:  Mov Disord       Date:  2011-03-29       Impact factor: 10.338

5.  Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.

Authors:  Diederick Stoffers; Jan Booij; Lisette Bosscher; Ania Winogrodzka; Erik C Wolters; Henk W Berendse
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-29       Impact factor: 9.236

6.  Clinical features and [11C]-CFT PET analysis of PARK2, PARK6, PARK7-linked autosomal recessive early onset Parkinsonism.

Authors:  Ji-feng Guo; Lei Wang; Dan He; Qiao-hong Ou Yang; Zhong-xiang Duan; Xue-wei Zhang; Li-luo Nie; Xin-xiang Yan; Bei-sha Tang
Journal:  Neurol Sci       Date:  2010-07-07       Impact factor: 3.307

7.  18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson's disease in various Hoehn & Yahr stages.

Authors:  Jian Wang; Cuan-Tao Zuo; Yu-Ping Jiang; Yi-Hui Guan; Zheng-Ping Chen; Jing-De Xiang; Li-Qin Yang; Zheng-Tong Ding; Jian-Jun Wu; Hui-Lin Su
Journal:  J Neurol       Date:  2007-03-02       Impact factor: 4.849

8.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

9.  Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.

Authors:  Kenji Ishibashi; Yuko Saito; Shigeo Murayama; Kazutomi Kanemaru; Keiichi Oda; Kiichi Ishiwata; Hidehiro Mizusawa; Kenji Ishii
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 10.  Neuroimaging of Parkinson's disease and atypical parkinsonism.

Authors:  Dennis J Zgaljardic; Andrew Feigin
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.